Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Astellas Pharma ( (JP:4503) ) has provided an announcement.
Astellas Pharma reported extraordinary losses of JPY 60.6 billion in its non-consolidated financial results for Q3 of fiscal year 2024, due to a significant decline in the value of shares of its subsidiary, Ganymed Pharmaceuticals GmbH. However, this loss did not affect the company’s consolidated financial results as it was offset in the consolidated statements.
More about Astellas Pharma
Astellas is a global life sciences company focused on innovative therapies in oncology, ophthalmology, urology, immunology, and women’s health. The company is dedicated to developing healthcare solutions for diseases with high unmet medical needs through its research and development programs.
YTD Price Performance: -2.89%
Average Trading Volume: 5,625
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $17.08B
Find detailed analytics on 4503 stock on TipRanks’ Stock Analysis page.
